MedTrace Logo

A Study on the Bone-health Effectiveness of Applying Recombinant Factor VIII Fc (rFVIIIFc) to Patients With Hemophilia A (Prototype A)

NCT05981274 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 45

Last updated 2024-04-10

No results posted yet for this study

Summary

Study Objectives\*

1. Provide a systematic evaluation of the treatment outcomes in patients with hemophilia A
2. Emphasize the importance and clinical benefits of rFVIII-Fc in joint and bone health.
3. Compare the clinical outcomes from 1 year before and after switching to EHL.
4. Exploratory: Identify biomarkers that could provide more useful and convenient evaluations of joint and bone health. (Time-saving and easy to monitor)

Conditions

  • Severe Hemophilia A Without Inhibitor

Interventions

DIAGNOSTIC_TEST

serum biomarker.

serum biomarker:CTX-II, COMP, hsCRP, TNF-a, CTX-I, sRANKL, OPG, and Osteopontin (OPN)

Sponsors & Collaborators

  • Tri-Service General Hospital

    lead OTHER

Eligibility

Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-07-14
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05981274 on ClinicalTrials.gov